Related Experiment Video
Updated: May 31, 2026

Porous Silicon Microparticles for Delivery of siRNA Therapeutics
Published on: January 15, 2015
Nanocarriers: a tool to overcome biological barriers in siRNA delivery
Avnesh Kumari1, Vineet Kumar, Sudesh Kumar Yadav
1Council of Scientific and Industrial Research (CSIR), Institute of Himalayan Bioresource Technology, Biotechnology Division, Nanobiology Lab, Palampur-176061 (HP), India.
Introduction:
siRNA has poor in vivo stability and has a plasma half life of only a few minutes after intravenous administration. These problems can be overcome by conjugating/encapsulating siRNA with various nanosystems. Surface modifications of such nanosystems can further improve the cellular uptake of siRNA-nanosystems. In this review, the authors have highlighted the problems encountered in siRNA delivery, conjugation strategies and nanosystems for siRNA delivery and for improving their in vivo delivery performance.
Areas Covered:
The authors briefly cover various problems encountered in siRNA delivery and discuss nanocarriers for overcoming these biological barriers.
Expert Opinion:
siRNA binding and unpacking are important factors for optimizing the interactions between siRNA and nanosystems. Several crucial conjugation parameters, such as the conjugation site of siRNA, and the nature of molecules to be conjugated (charge, molecular weight and hydrophobicity), should be carefully considered for maximising delivery efficiency of siRNA conjugated nanosystems.
More Related Videos
Related Concept Videos
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Experimental RNAi
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Modified-Release Drug Delivery Systems: Site-Targeted

